Evidence map›Paper›PMID 27429364›Full record

ArticleAging2016

Repurposing Tecfidera for cancer.

Laurence Booth, Mark Malkin, Paul Dent

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Functional analysis of Cullin 3 E3 ligases in tumorigenesis.Biochimica et biophysica acta. Reviews on cancer · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Laurence BoothDepartments of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, and the Massey Cancer Center, Richmond, VA 23298, USA.
Mark MalkinDepartment of Neurology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Paul DentDepartments of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, and the Massey Cancer Center, Richmond, VA 23298, USA.

Funding

Pemetrexed and sildenafil for lung cancerR01CA192613 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DENT, PAUL · 2015 to 2019
$1.6M
NCI NIH HHS R01 CA192613
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug RepositioningAntineoplastic AgentsDimethyl FumarateHumansImmunosuppressive AgentsNeoplasmsAntineoplastic AgentsDimethyl FumarateImmunosuppressive Agentsdimethyl fumarate (DMF)glioblastoma multiformeJakafimonomethyl fumarate (MMF)oncologyruxolitinibTecfidera

Identifiers

PMID27429364
PMCPMC4993329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.